Royalty Report: Medical, Supply, Surgical – Collection: 27346

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Medical
  • Supply
  • Surgical
  • Device
  • cardiac
  • Coating
  • Stent

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27346

License Grant
Biograft peripheral vascular graft; Biograft is used to bypass occluded blood vessels and is produced from modified human umbilical veins; for use in lower limb vascular reconstructions when a saphenous vein is not available.

IPSCIO Record ID: 27347

License Grant
The Company entered into an agreement with an undisclosed Licensor for card-vascular products.
License Property
Bio-Vascular Probe is a flexible shaft with varying sizes of bulbous tips on either end.  Biograft is used to bypass occluded blood vessels and is produced from modified human umbilical veins.
Field of Use
Surgeons use the Bio-Vascular Probe to locate occlusions or blockages in arteries and to ascertain the blood flow characteristics of arteries.

IPSCIO Record ID: 336324

License Grant
Licensor has been advised that Licensee will assign the Patent Sublicense Agreement to a new Licensee. The assignment provisions of the Sublicense Agreement shall continue in full force with changes to the royalty amount.

Per the Patent Sublicense Agreement,, Licensor hereby grants to Licensee a personal, nonexclusive sublicense under the Sublicensed Patent to make, have made for its own account, use, and import Licensed Products, and to sell, lease, offer for sale and otherwise transfer Licensed Products as hereinafter provided. Licensee or an Affiliate of Licensee may sell or transfer Licensed Products directly to End Users. Licensee or, in the event that Licensee first sells or transfers Licensed Products to any Affiliate of Licensee, such Affiliate, may also sell or transfer Licensed Products to Distributors for resale to End Users; provided, however, that any such Distributor must resell the Licensed Products to End Users in unchanged form, and provided further, that there shall be no more than one distribution channel for Licensed Products (i.e., one of Licensee or an affiliate of Licensee or a Distributor) in any specific country in the world. This sublicense specifically excludes any right of Licensee (or any Affiliate or Distributor of Licensee) to sell or otherwise transfer Licensed Products to OEM Customers.

License Property
Sublicensed Patent shall mean United States Patent No. 6,436,135 issued to David Goldfarb, MD. on August 20, 2002, and any reissues and/or any reexaminations thereof.
United States Patent No. 6,436,135 – Prosthetic vascular graft
Field of Use
The Licensee's EndoFit Aortic Stent Graft is a line of endovascular grafts used to treat aortic aneurysms, a weakening and ballooning of the aorta.

Field of Use shall mean the field of endovascular products i.e., medical products that are placed within the arteries or veins of the human body. The Field of Use expressly excludes any surgical prosthetic device intended in whole or in part to replace any portion of any artery, vein or other vessel or conduit within the human body, including but not limited to bypass grafts, dialysis grafts, aortic grafts or thoracic grafts.

IPSCIO Record ID: 336323

License Grant
Licensor hereby grants to Licensee a personal, nonexclusive sublicense under the Sublicensed Patent to make, have made for its own account, use, and import Licensed Products, and to sell, lease, offer for sale and otherwise transfer Licensed Products as hereinafter provided. Licensee or an Affiliate of Licensee may sell or transfer Licensed Products directly to End Users. Licensee or, in the event that Licensee first sells or transfers Licensed Products to any Affiliate of Licensee, such Affiliate, may also sell or transfer Licensed Products to Distributors for resale to End Users; provided, however, that any such Distributor must resell the Licensed Products to End Users in unchanged form, and provided further, that there shall be no more than one distribution channel for Licensed Products (i.e., one of Licensee or an affiliate of Licensee or a Distributor) in any specific country in the world. This sublicense specifically excludes any right of Licensee (or any Affiliate or Distributor of Licensee) to sell or otherwise transfer Licensed Products to OEM Customers.
License Property
Sublicensed Patent shall mean United States Patent No. 6,436,135 issued to David Goldfarb, MD. on August 20, 2002, and any reissues and/or any reexaminations thereof.
United States Patent No. 6,436,135 – Prosthetic vascular graftof the Sublicensed Patent, and (iii) that are within the Field of Use.
Field of Use
Field of Use shall mean the field of endovascular products i.e., medical products that are placed within the arteries or veins of the human body. The Field of Use expressly excludes any surgical prosthetic device intended in whole or in part to replace any portion of any artery, vein or other vessel or conduit within the human body, including but not limited to bypass grafts, dialysis grafts, aortic grafts or thoracic grafts.

IPSCIO Record ID: 27295

License Grant
The Company entered into an agreement with an undisclosed Licensor for a small diameter graft for vascular surgery.

IPSCIO Record ID: 286596

License Grant
Licensor hereby grants to Licensee an exclusive, perpetual, sub-licensable license to Licensor’s Intellectual Property, Trade Marks (TM), and all technical knowhow in the Fields of Use including Coronary Artery Bypass Grafting, Peripheral Vascular Bypass grafting and other Vascular Surgeries, to enable it to file for regulatory approvals, CE certification, preclinical and clinical studies, manufacture, distribute, market and commercialize the product in the Territory.

Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensor’s IP, Trade Marks (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all countries outside the Territory if in any country outside the Territory that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.

Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensees right to distribute is for the Territory in the Field of Use only.

License Property
Products shall refer to the products listed below
DuraGraft – Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries. The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee. Licensor will assist Licensee at Licensee’s cost, with technology transfer to allow Licensee to complete the manufacturing of the DuraGraft product at its ISO13485 certified site in the Territory or and release the product for commercial use in Licensee territories.  Licensor will transfer all Intellectual Property and technologies to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

A CE Marked Product – Notified Body is BSI, Netherlands

Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensor’s corporate name, other trade names, model names and trademarks, including DURAGRAFT.

Intellectual Property and technologies are to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

Field of Use
Field of Use shall refer to use of the Product to preserve vascular conduits used in bypasses in cardiovascular surgery, peripheral bypass surgery and other vascular surgeries.

DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure.

IPSCIO Record ID: 27403

License Grant
The Company owns exclusive, worldwide, perpetual licenses to develop, manufacture and market its Flo-Rester products from an undisclosed Licensor.
License Property
Flo-Rester products are vessel occluders manufactured from medical grade silicone.  The Flo-Rester products are designed to interrupt blood flow in arteries and to stent (hold open) them during surgery, thereby facilitating the suturing together of vessels.  Flo-Rester consists of a flexible shaft with small bulbs at each end that are inserted into the blood vessel at the point where the artery bypass is sutured to the artery to stop the blood flow.

IPSCIO Record ID: 3101

License Grant
The Licensee has entered into multiple license agreements with three Universities.  Under the terms of the License Agreements, the Licensee acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves.

The licensed technologies include the rights to issued patents and patents pending in the United States and international markets.

License Property
Avance® Nerve Graft is a human tissue for transplantation.  Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect.

The AxoGuard® Nerve Protector is indicated for the repair of peripheral nerve injuries where there is no gap. The device is supplied sterile and is intended for one-time use.

Field of Use
The Licnesee is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration.

In order to improve surgical reconstruction and regeneration of peripheral nerves, the Licensee has developed and licensed technologies, which are used in its products. Its product portfolio includes Avance® Nerve Graft which the Licensee believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, an implant that protects nerves during the body's healing process after surgery.

IPSCIO Record ID: 299236

License Grant
Under the initial agreement, the Canadian Licensor agreed to license on a co-exclusive certain patent rights, license rights, and technology.

This agreement is extending Licensee’s worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Licensor Technology in the Peripheral Vascular Field of Use and the GI Field of Use.

Licensor newly grants its licensee, the right for Licensee to have third party Distributors distribute Eligible Peripheral Vascular and/or GI Products.

This agreement is co-exclusive with an option to become exclusive.

License Property
This agreement is for paclitaxel or certain other agents as a coating for certain medical devices.

The license agreement regards paclitaxel-eluting stent products and related technologies.  Paclitaxel is released from the balloon or stent to prevent scar tissue formation in the blood vessel that can re-obstruct the artery (restenosis).

Field of Use
As used herein, the Coronary Vascular Field of Use means endoluminal vascular Licensed Applications for the treatment and/or prevention of disease of the coronary arteries and their branches, or other vasculature providing blood flow to the heart.

As used herein, the Peripheral Vascular Field of Use means the endoluminal vascular licensed applications for the treatment or preventionof disease of the peripheral blood vessels of the body.  Notwithstanding the foregoing, Peripheral Vascular Field of Use excludes any application in the Coronary Vascular Field of Use.  

GI Field of Use means the endoluminal licensed applications for the treatment or prevention of disease of the alimentary tract or liver.

IPSCIO Record ID: 307236

License Grant
Licensor hereby grants to Licensee an exclusive, perpetual, sub-licensable license to Licensor’s Intellectual Property, Trade Marks (TM), and all technical knowhow in the Fields of Use including Coronary Artery Bypass Grafting, Peripheral Vascular Bypass grafting and other Vascular Surgeries, to enable it to file for regulatory approvals, ISO 13485 certification, preclinical and clinical studies, manufacture, distribute, market and commercialize the product in the specified Territory.

Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensor’s IP, TradeMark (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all Licensed Territories. Territories are those that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.

Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase from Licensor, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensee’s right to distribute is for the Territory in the Field of Use only.

License Property
Products shall refer to the products (DuraGraft) listed
DuraGraft – Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries

The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee.

Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensor’s corporate name, other trade names, model names and trademarks.

Field of Use
Field of Use shall refer to use of the Product to preserve vascular conduits used in bypasses in cardiovascular surgery, peripheral bypass surgery and other vascular surgeries.

DuraGraft® is a one time intraoperative vascular graft treatment that maintains endothelial function and structure, thereby reduacing the incidence and complications of graft failure thereby improving clinical outcomes

IPSCIO Record ID: 2357

License Grant
Licensor and Licensee have  entered into agreement relating to certain technology.
License Property
'Licensed Products' shall mean any product, good, or item within the Field, produced in whole or in part, using a part or all of the technology embodied in Licensed Patents, and made of, but not limited to, Fluorinated Hydrocarbons (including, but not limited to, PTFE, ePTFE, FEP, PFA, HFP and VF).

A. Soft Tissue Includes Gore patch products used in the following applications
i)  Reconstruction of hernias and soft tissue deficiencies, such as abdominal wall defects, diaphragmatic hernia, laparoscopic hernia, pelvic floor and lid reconstruction, ventral hernia, laparoscopic inguinal hernia, muscle flap reconstruction, vaginal prolapse, rectal prolapse, scrotal hernia, gastric banding and temporary facial bridging; and
ii)  Plastic and reconstructive surgery, such as malarplasty, mentoplasty, rhinoplasty, maxilloplasty, frontal defects, reconstructive lip augmentations, orbital repair, facial folds, facial slings and auricuoplasty.

B. Cardiovascular Includes Gore patch products used in cardiovascular and cardiac patching, such as carotid patch, angioplasty, profundaplasty, AV access graft patching, septal defects, outflow tracts, aneurysm repair and other patch angioplasty.

C. Surgical Membrane/Adhesion Limiting Includes Gore patch products used in the following applications
i)   Reconstruction or repair of the peritoneum, where minimal adhesions to a prosthetic material are desired, such as infertility surgery, gynecological surgery and gynecological and surgical oncology;
ii)  Temporary or permanent prosthesis for the repair of dura mater during neurosurgery, such as tumor resection, tethered cord releases, trauma repair and Chiari decompression;
iii) Reconstruction of the pericardium where minimal adhesions are desired; and
iv)  Wrap for pedicled arterial conduits.

IPSCIO Record ID: 222532

License Grant
The purpose of this amendment is to (i) transfer the rights and obligations of Party A to Party C, (ii) amend the royalty payment provision set forth in the Agreement, and (iii) amend the termination provision set forth in the Agreement.

Accordingly, this letter confirms the assignment of the rights and obligations of Party A to Party C and acknowledges the consent thereto by Party B.

License Property
Royalty Obligations means Net Sales” means the gross amount received on the sale of Royalty Products by Licensee.

Royalty Product means a product developed and sold by Party C that is covered by a Valid Claim of an Unexpired patent that is included within the Patent Rights.

Patent Right or Patent Rights means (x) U.S. Patent No. 6,241,761 (Stented Grafts for Coupling Vascular Members) issued on June 5, 2001, and U.S. Patent No. 6,241,764 (Stented Grafts Coupling Vascular Members) issued on June 5, 2001 (including any divisions, continuations, reexaminations, reissue substitution applications thereof and foreign applications based thereon) and (y) any and all patents issuing therefrom and extensions thereof.

Field of Use
This agreement pertains to the medical industry relating to stented grafts for coupling vascular members.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.